IRA revisions now exempt multi-indication orphan drugs from price negotiations, improving lifecycle economics and encouraging ...
Orphan drugs are forecast to surpass $400 billion in 2032 sales, driven by accelerating rare disease innovation despite regulatory volatility, pricing pressures, and capital competition from ...
Report reveals that FDA temperament and blockbuster drugs fall short of disrupting the ever-increasing orphan drug market LONDON – 13 March 2026 – Evaluate, the leading provider of market insights for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results